Academic Journal
Treatment with etanercept and low monocyte concentration contribute to the risk of invasive aspergillosis in patients post allogeneic stem cell transplantation
| العنوان: | Treatment with etanercept and low monocyte concentration contribute to the risk of invasive aspergillosis in patients post allogeneic stem cell transplantation |
|---|---|
| المؤلفون: | Zoran, Tamara, Weber, Michael, Springer, Jan, White, P. Lewis, Bauer, Joachim, Schober, Annika, Loeffler, Claudia, Seelbinder, Bastian, Huenniger, Kerstin, Kurzai, Oliver, Scherag, Andre, Schauble, Sascha, Morton, Charles O. (R16967), Einsele, Hermann, Linde, Jorg, Loeffler, Juergen |
| المساهمون: | School of Science and Health (Host institution) |
| بيانات النشر: | U.K., Nature Publishing Group |
| سنة النشر: | 2019 |
| المجموعة: | University of Western Sydney (UWS): Research Direct |
| مصطلحات موضوعية: | 060505 - Mycology, 110899 - Medical Microbiology not elsewhere classified, 920109 - Infectious Diseases, aspergillosis, Aspergillus fumigatus, allogeneic stem cells, transplantation, etanercept, monocytes |
| الوصف: | Invasive aspergillosis (IA) is a life-threatening complication among allogeneic hematopoietic stem cell transplant (alloSCT) recipients. Despite well known risk factors and different available assays, diagnosis of invasive aspergillosis remains challenging. 103 clinical variables from patients with hematological malignancies and subsequent alloSCT were collected. Associations between collected variables and patients with (n = 36) and without IA (n = 36) were investigated by applying univariate and multivariable logistic regression. The predictive power of the final model was tested in an independent patient cohort (23 IA cases and 25 control patients). Findings were investigated further by in vitro studies, which analysed the effect of etanercept on A. fumigatus-stimulated macrophages at the gene expression and cytokine secretion. Additionally, the release of C-X-C motif chemokine ligand 10 (CXCL10) in patient sera was studied. Low monocyte concentration (p = 4.8 × 10−06), severe GvHD of the gut (grade 2–4) (p = 1.08 × 10−02) and etanercept treatment of GvHD (p = 3.5 × 10−03) were significantly associated with IA. Our studies showed that etanercept lowers CXCL10 concentrations in vitro and ex vivo and downregulates genes involved in immune responses and TNF-alpha signaling. Our study offers clinicians new information regarding risk factors for IA including low monocyte counts and administration of etanercept. After necessary validation, such information may be used for decision making regarding antifungal prophylaxis or closely monitoring patients at risk. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | |
| اللغة: | English |
| Relation: | Scientific Reports--2045-2322-- Vol. 9 Issue. 1 No. 17231 pp: - |
| DOI: | 10.1038/s41598-019-53504-8 |
| الاتاحة: | https://doi.org/10.1038/s41598-019-53504-8 https://hdl.handle.net/1959.7/uws:53714 |
| Rights: | © The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| رقم الانضمام: | edsbas.AB149928 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/s41598-019-53504-8 |
|---|